Michael Hedvat
机构: Associate Director at Xencor Inc.
每年引用次数
引用次数
引用: 2,596
H-指数: 20
I10-指数 : 21
出版物: 69
Stimulation of the HER-kinase axis promotes resistance to the Raf-kinase activity of sorafenib, which can be reversed by the addition of MEK inhibitor U0126
Anjali Jain , Michael Hedvat , Schmidt Joanna , David Agus
Cancer Research 67 5412 -5412
2007
The Src family kinase inhibitor, dasatinib, inhibits angiogenesis in vitro and in vivo
Wei Liang , Frank Lee , Michael Hedvat , Wei Wen
Cancer Research 68 270 -270
2
2008
Bispecific checkpoint inhibitor antibodies
Gregory Moore , Alex Nisthal , Matthew Bernett , John Desjarlais
23
2017
The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
Michael Hedvat , Dennis Huszar , Andreas Herrmann , Joseph M. Gozgit
Cancer Cell 16 ( 6) 487 -497
438
2009
Selected Approaches for Rational Drug Design and High Throughput Screening to Identify Anti-Cancer Molecules
Michael Hedvat , Luni Emdad , Swadesh K. Das , Keetae Kim
Anti-cancer Agents in Medicinal Chemistry 12 ( 9) 1143 -1155
29
2012
Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas.
Fan Yang , Timothy E. Van Meter , Ralf Buettner , Michael Hedvat
Molecular Cancer Therapeutics 7 ( 11) 3519 -3526
84
2008
Sorafenib Induces Growth Arrest and Apoptosis of Human Glioblastoma Cells through the Dephosphorylation of Signal Transducers and Activators of Transcription 3
Fan Yang , Christine Brown , Ralf Buettner , Michael Hedvat
Molecular Cancer Therapeutics 9 ( 4) 953 -962
96
2010
Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways.
Fan Yang , Veronica Jove , Hong Xin , Michael Hedvat
Molecular Cancer Research 8 ( 1) 35 -45
83
2010
Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells.
Belal Azab , Rupesh Dash , Swadesh K. Das , Sujit K. Bhutia
Journal of Cellular Physiology 227 ( 5) 2145 -2153
40
2012
Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480
Hong Xin , Andreas Herrmann , Karen Reckamp , Wang Zhang
Cancer Research 71 ( 21) 6601 -6610
92
2011
Targeting Mcl-1 for the therapy of cancer
Bridget A Quinn , Rupesh Dash , Belal Azab , Siddik Sarkar
Expert Opinion on Investigational Drugs 20 ( 10) 1397 -1411
139
2011
Role of Excitatory Amino Acid Transporter‐2 (EAAT2) and glutamate in neurodegeneration: Opportunities for developing novel therapeutics
Keetae Kim , Seok-Geun Lee , Timothy P. Kegelman , Zhao-Zhong Su
Journal of Cellular Physiology 226 ( 10) 2484 -2493
252
2011
697 Tumor-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors
Rumana Rashid , Irene Leung , Norm Bartlow , Charles Bakhit
Journal for ImmunoTherapy of Cancer 8
2020
Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARγ
Michael Hedvat , Anjali Jain , Dennis A Carson , Lorenzo M Leoni
Cancer Cell 5 ( 6) 565 -574
34
2004
Alkylation of cysteine 468 in Stat3 defines a novel site for therapeutic development
Ralf Buettner , Renzo Corzano , Rumana Rashid , Jianping Lin
ACS Chemical Biology 6 ( 5) 432 -443
49
2011
Abstract# 5627: Sorafenib inhibits STAT3 signaling, cell proliferation and survival of human glioblastomas
Fan Yang , Christine Brown , Ralf Buettner , Michael Hedvat
Cancer Research 69 ( 9_Supplement) 5627 -5627
2009
Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity (vol 108, pg 8785, 2011)
Rupesh Dash , Belal Azab , Bridget A Quinn , Xuening Shen
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 114 ( 22) E4522 -E4523
2017
Simultaneous checkpoint-checkpoint or checkpoint-costimulatory receptor targeting with bispecific antibodies promotes enhanced human T cell activation
Michael Hedvat , Christine Bonzon , Matthew J Bernett , Gregory L Moore
Cancer Research 78 ( 13_Supplement) 2784 -2784
9
2018
Anti-PD1 x anti-ICOS bispecific antibody XmAb23104 brings together PD1 blockade and ICOS costimulation to promote human T cell activation and proliferation
Gregory Moore , Michael Hedvat , Matthew Bernett , Christine Bonzon
JOURNAL FOR IMMUNOTHERAPY OF CANCER 5
3
2017
PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof
Matthew Bernett , John R Desjarlais , Michael Hedvat , Suzanne Schubbert
1
2022